

# Contents

**Preface viii**

**Acknowledgments ix**

**Dedication x**

**1 The History and Impact of Genetics in Medicine 1**

Gregor Mendel and the Laws of Inheritance 1  
DNA as the Basis of Inheritance 3  
The Fruit Fly 4  
The Origins of Medical Genetics 4  
Major New Developments 7  
The Societal Impact of Advances in Genetics 7

**Section A: The Scientific Basis of Human Genetics**

**2 The Cellular and Molecular Basis of Inheritance 10**

The Cell 10  
DNA: The Hereditary Material 10  
Chromosome Structure 12  
Types of DNA Sequence 12  
Transcription 15  
Translation 15  
The Genetic Code 16  
Regulation of Gene Expression 16  
RNA-Directed DNA Synthesis 19  
Mutations 19  
Mutations and Mutagenesis 23

**3 Chromosomes and Cell Division 26**

Human Chromosomes 26  
Methods of Chromosome Analysis 27  
Molecular Cytogenetics 29  
Chromosome Nomenclature 29  
Cell Division 31  
Gametogenesis 34  
Chromosome Abnormalities 34

**4 Finding the Cause of Monogenic Disorders by Identifying Disease Genes 44**

Position-Independent Identification of Human Disease Genes 44  
Positional Cloning 45  
The Human Genome Project 47

Identifying the Genetic Etiology of Monogenic Disorders by Next-Generation Sequencing 48

**5 Laboratory Techniques for Diagnosis of Monogenic Disorders 51**

Polymerase Chain Reaction 51  
Application of DNA Sequence Polymorphisms 52  
Nucleic Acid Hybridization Techniques 54  
Mutation Detection 55  
Sequencing-Based Methods 57  
Dosage Analysis 61  
Genome Sequencing as a Clinical Diagnostic Test 63

**6 Patterns of Inheritance 67**

Family Studies 67  
Mendelian Inheritance 67  
Multiple Alleles and Complex Traits 76  
Anticipation 76  
Mosaicism 77  
Uniparental Disomy 77  
Genomic Imprinting 78  
Mitochondrial Inheritance 81

**7 Population and Mathematical Genetics 84**

Allele Frequencies in Populations 84  
Genetic Polymorphism 89  
Segregation Analysis 90  
Genetic Linkage 90  
Medical and Societal Intervention 94

**8 Risk Calculation 96**

Probability Theory 96  
Autosomal Dominant Inheritance 97  
Autosomal Recessive Inheritance 99  
X-Linked Recessive Inheritance 100  
The Use of Linked Markers 101  
Bayes' Theorem and Prenatal Screening 102  
Empiric Risks 102

**9 Developmental Genetics 105**

Fertilization and Gastrulation 105  
Developmental Gene Families 106  
The Pharyngeal Arches 118  
The Role of Cilia in Developmental Abnormalities 119  
The Limb as a Developmental Model 119  
Developmental Genes and Cancer 121  
Positional Effects and Developmental Genes 122

Hydatidiform Moles 122  
 Epigenetics and Development 123  
 Sex Determination and Disorders of Sex  
 Development 127  
 Twinning 131

## Section B: Genetics in Medicine and Genomic Medicine

### 10 Common Disease, Polygenic, and Multifactorial Genetics 136

Types and Mechanisms of Genetic Susceptibility 136  
 Approaches to Demonstrating Genetic Susceptibility to Common Diseases 137  
 Polygenic Inheritance and the Normal Distribution 138  
 Multifactorial Inheritance—the Liability/Threshold Model 139  
 Identifying Genes That Cause Multifactorial Disorders 140  
 Polygenic Risk Scores 144  
 Disease Models for Multifactorial Inheritance 144

### 11 Screening for Genetic Disease 151

Screening Those at High Risk 151  
 Carrier Testing for Autosomal Recessive and X-Linked Disorders 151  
 Presymptomatic Diagnosis of Autosomal Dominant Disorders 153  
 Ethical Considerations in Carrier Detection and Predictive Testing 154  
 Population Screening 154  
 Criteria for a Screening Program 155  
 Prenatal and Postnatal Screening 156  
 Population Carrier Screening 158  
 Genetic Registers 159

### 12 Hemoglobin and the Hemoglobinopathies 161

Structure of Hemoglobin 161  
 Developmental Expression of Hemoglobin 162  
 Globin Chain Structure 162  
 Synthesis and Control of Hemoglobin Expression 163  
 Disorders of Hemoglobin 163  
 Clinical Variation of the Hemoglobinopathies 169  
 Antenatal and Newborn Hemoglobinopathy Screening 169

### 13 Immunogenetics 171

Immunity 171  
 Innate Immunity 171  
 Specific Acquired Immunity 174  
 Inherited Immunodeficiency Disorders 178  
 Blood Groups 181

### 14 The Genetics of Cancer . . . and Cancer Genetics 184

Differentiation Between Genetic and Environmental Factors in Cancer 184

Oncogenes 186  
 Tumor Suppressor Genes 189  
 Epigenetics and Cancer 192  
 Genetics of Common Cancers 194  
 DNA Tumor Profiling, Mutational Signatures, and Tumor Mutational Burden 195  
 Inherited Cancer Syndromes 197  
 Genetic Counseling in Familial Cancer 202  
 Screening for Familial Cancer 203  
 What Treatment Is Appropriate? 208

### 15 Pharmacogenomics, Precision Medicine, and the Treatment of Genetic Disease 210

Pharmacogenomics 210  
 Drug Metabolism 210  
 Genetic Variations Revealed by the Effects of Drugs 211  
 Precision Medicine 213  
 Treatment of Genetic Disease 215  
 Therapeutic Applications of Recombinant DNA Technology 218  
 Gene Therapy 218  
 RNA Modification 221  
 Targeted Gene Correction 222  
 Stem Cell Therapy 222

## Section C: Clinical Genetics, Counseling, and Ethics

### 16 Congenital Abnormalities, Dysmorphic Syndromes, and Intellectual Disability 227

Incidence 227  
 Definition and Classification of Birth Defects 228  
 Genetic Causes of Malformations 232  
 Environmental Agents (Teratogens) 237  
 Malformations of Unknown Cause 240  
 Counseling 241  
 Intellectual Disability 241

### 17 Chromosome Disorders 250

Incidence of Chromosome Abnormalities 250  
 Disorders of the Sex Chromosomes 254  
 “Classic” Chromosome Deletion Syndromes 258  
 Chromosome Microarray/Microarray-Comparative Genomic Hybridization 259  
 Chromosome Disorders and Behavioral Phenotypes 265  
 Chromosome Breakage Syndromes 265  
 Indications for Chromosome Microarray Analysis 268

### 18 Inborn Errors of Metabolism 271

Disorders of Amino Acid and Peptide Metabolism 271  
 Disorders of Carbohydrate Metabolism 276  
 Disorders of Steroid Metabolism 277  
 Disorders of Lipid and Lipoprotein Metabolism 277  
 Lysosomal Storage Disorders 278  
 Disorders in the Metabolism of Purines, Pyrimidines, and Nucleotides 282  
 Disorders of Porphyrin and Heme Metabolism 282

Disorders in the Metabolism of Trace Elements and Metals 283  
Peroxisomal Disorders 284  
Disorders of Fatty Acid and Ketone Body Metabolism 285  
Disorders of Energy Metabolism 286  
Prenatal Diagnosis of Inborn Errors of Metabolism 287

## **19 Mainstream Monogenic Disorders 289**

Neurological Disorders 289  
CADASIL and Early-Onset Dementia 290  
Inherited Peripheral Neuropathies 292  
Motor Neurone Disease 295  
Neurocutaneous Disorders 295  
Muscular Dystrophies 299  
Respiratory Disorders 303  
Inherited Cardiac Conditions 306  
Connective Tissue Disorders 308  
Renal Disorders 312  
Blood Disorders 316

## **20 Prenatal Testing and Reproductive Genetics 322**

Techniques Used in Prenatal Diagnosis 322  
Antenatal and Prenatal Screening 324  
Indications for Prenatal Testing 329  
Special Problems in Prenatal Diagnosis 331  
Termination of Pregnancy 332  
Preimplantation Genetic Diagnosis 332  
Assisted Conception and Implications for Genetic Disease 333

Prenatal Treatment 336

## **21 Genetic Counseling 338**

Definition 338  
Establishing the Diagnosis 338  
Calculating and Presenting the Risk 339  
Discussing the Options 340  
Communication and Support 340  
Genetic Counseling—Directive or Non-directive? 340  
Outcomes in Genetic Counseling 341  
Special Issues in Genetic Counseling 341

## **22 Ethical and Legal Issues in Medical Genetics 345**

General Principles 345  
Ethical Dilemmas in the Genetics Clinic 347  
Ethical Dilemmas and the Public Interest 350

## **Glossary 355**

## **Appendix: Websites and Clinical Databases 372**

## **Multiple-Choice Questions 374**


## **Case-Based Questions 382**

## **Multiple-Choice Answers 387**

## **Case-Based Answers and Discussion 396**

## **Clinical Scenario Answers and Discussion 403**

## **Index 412**



• **Fig. 11.4** Renal ultrasonogram of an asymptomatic person with tuberous sclerosis showing abnormal echogenicity attributed to presumed angiomyolipomata (arrows).

well as renal ultrasonography to identify the cysts known as angiomyolipoma(ta) (Fig. 11.4). Use of these relatively non-invasive tests in relatives of persons with TSC can often detect evidence of the condition in asymptomatic persons, especially as sequencing of the *TSC1* and *TSC2* genes is not guaranteed to identify a pathogenic variant.

Similarly, assessment for Marfan syndrome involves ophthalmic examination for evidence of ectopia lentis, echocardiography for measurement of the aortic root diameter, and sometimes magnetic resonance imaging of the lumbar spine to look for evidence of dural ectasia—all of which are important criteria. Their absence does not exclude the diagnosis, and further assessments are necessary if sequencing of the Marfan gene, *FBN1*, reveals a variant of uncertain significance, which is not uncommon for this gene.

## Biochemical Tests

Biochemical tests are very useful in some autosomal dominant disorders. Examples include the use of serum cholesterol levels in those at risk of familial hypercholesterolemia (pp. 147, 277), although genetic testing is increasingly available, as well as assay of the appropriate urinary porphyrins or the specific enzyme deficiency in the various dominantly inherited porphyrias (p. 282).

## Ethical Considerations in Carrier Detection and Predictive Testing

One of the main reasons for determining the carrier status of a person at risk of an autosomal or X-linked recessive disorder is to help couples make an informed choice when having children. For some, however, the knowledge that there is a significant risk of having an affected child may present options and choices that they would rather avoid. Knowledge of the risk and the awareness that prenatal diagnosis is available may create a sense of guilt whichever decision

is taken—either to have a child knowing it could be affected, or to have prenatal testing that may lead to termination of pregnancy. The latter option is especially difficult when the prognosis of the disease cannot be stated with certainty because of its variability or reduced penetrance, or if treatment may be developed in time to help the child.

Experience with these potential dilemmas has resulted in normal practice promoting the flow of information within families, rather than from professionals. In general this approach works well, but professional dilemmas can arise if family members refuse to communicate with one another even when the condition carries significant morbidity and the risk is high, particularly with X-linked conditions.

Presymptomatic diagnosis for some late-onset autosomal dominant disorders has clear medical advantages in relation to early intervention and prevention. In familial adenomatous polyposis, for example (p. 197), colonoscopy looking for the presence of colonic polyps can be offered as a regular screening procedure to those who have been shown to be at high risk of developing colonic cancer by molecular studies. Conversely, individuals who have not inherited a pathogenic variant in the *APC* gene do not need to be screened.

In contrast, for persons at risk for Huntington disease (HD), a disorder for which there is currently no effective treatment to delay onset or progression, the benefit of predictive testing is not immediately obvious. The same is true for familial forms of Alzheimer disease, motor neurone disease, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, and the spinocerebellar ataxias. Although choice is often considered to be of paramount importance in genetic counseling for those at risk of inherited disorders, remember that those considering presymptomatic or predictive testing should proceed only if they can give truly informed consent and are free from coercion from others. It is possible that employers, life insurance companies, and society in general will put indirect, and on occasion direct, pressure on those at high risk to be tested (p. 350). Indeed, there are examples in which individuals at risk of HD have received prejudicial treatment in relation to employment, and higher than average insurance premiums can be expected on the basis of the family history alone.

Predictive testing for late-onset disorders can, in theory, be used for children and minors, but this can be a contentious issue. Parents sometimes argue that it is their right to know the status of their child(ren). However, this conflicts with upholding the principle of individual autonomy wherever possible. Presymptomatic testing of children is therefore usually discouraged unless an early medical intervention or screening is beneficial for the disorder, which is certainly true for a number of the familial cancer conditions. The issue of genetic testing of children is addressed more fully in Chapter 22 (p. 348).

## Population Screening

One definition of population screening is: “The systematic application of a test or inquiry, to identify individuals at sufficient risk of a specific disorder to warrant further investigation or treatment, amongst persons who have not sought medical attention on account of symptoms of that disorder.” Neonatal screening for phenylketonuria is the paradigm of a good screening program and has been available since 1969 in the United Kingdom, with screening for congenital hypothyroidism from 1981. In the United Kingdom, since 1996, population screening has been overseen by the UK National



### • BOX 11.2 Current Nationally-Managed Screening Programs in the United Kingdom (for Conditions With Genetic or Potentially Genetic Causes)

#### Antenatal

Down syndrome  
Sickle-cell disease  
Thalassemia  
Structural abnormalities (fetal anomaly scanning at 18–20 weeks' gestation)

#### Newborn Bloodspot

Phenylketonuria  
Congenital hypothyroidism  
Sickle-cell disease  
Cystic fibrosis  
Medium-chain acyl-CoA dehydrogenase deficiency  
Maple syrup urine disease  
Isovaleric acidemia  
Glutaric aciduria type 1  
Homocystinuria

#### Newborn and Infant Physical Examination

Newborn hearing

#### Adult

Breast cancer (women >50 years old)  
Bowel cancer (> 60 years old, fecal occult blood)  
Sight-threatening diabetic retinopathy  
Abdominal aortic aneurysm (men >65 years old)

Screening Committee (NSC) and Public Health England (PHE). The current, nationally managed, screening programs are listed in Box 11.2. The implementation of a screening program is a huge logistical exercise requiring financial and statistical expertise and technology resources, as well as practical mechanisms to introduce the program and monitor outcomes and quality assurance.

### Criteria for a Screening Program

Criteria for a screening program can be considered under the headings of the disease, the test and the practical aspects of the program (Box 11.3). These criteria apply equally to prenatal screening, also addressed in Chapter 20.

### • BOX 11.3 Criteria for a Screening Program

#### Disease

High incidence in target population  
Serious effect on health  
Treatable or preventable

#### Test

Non-invasive and easily carried out  
Accurate and reliable (high sensitivity and specificity)  
Inexpensive

#### Program

Widespread and equitable availability  
Voluntary participation  
Acceptable to the target population  
Full information and counseling provided

### The Disease

To justify the applied effort and resources allocated to screening, the disease should be sufficiently common and have potentially serious effects that are amenable to prevention or amelioration. This may involve early treatment, as for phenylketonuria diagnosed in the neonatal period (p. 271), or the offer of termination of pregnancy for disorders that cannot be treated effectively and are associated with serious morbidity and/or mortality.

### The Test

The test should be accurate and reliable with high **sensitivity** and **specificity**. Sensitivity refers to the proportion of cases that are detected. A measure of sensitivity can be made by determining the proportion of false-negative results (i.e., how many cases are missed). Thus, if a test detects only 70 of 100 cases, it shows a sensitivity of 70%. Specificity refers to the extent to which the test detects only affected individuals. If unaffected people test positive, these are referred to as false positives. Thus, if 10 of 100 unaffected individuals have a false-positive test result, the test shows a **specificity** of 90%. Table 11.2 explains this further. This feeds into the **positive predictive value** of a screening test, which is the proportion of positive tests that are true positives; this is illustrated in Table 11.3.

### The Program

The program should be offered in a fair and equitable manner and should be widely available. It must also be morally acceptable to a substantial proportion of the population to which it is offered.

**TABLE 11.2** Sensitivity and specificity

	DISEASE STATUS	
	Affected	Unaffected
<b>Screening Test Result</b>		
Positive	a (true positive)	b (false positive)
Negative	c (false negative)	d (true negative)
Sensitivity: $a/(a + c)$	— proportion of true positives	
Specificity: $d/(d + b)$	— proportion of true negatives	

**TABLE 11.3** In this hypothetical scenario a screening test for congenital adrenal hyperplasia has been implemented, with the following results

CONGENITAL ADRENAL HYPERPLASIA PRESENT		CONGENITAL ADRENAL HYPERPLASIA ABSENT	
Positive	Negative	Positive	Negative
96	4	4980	510,100
Positive predictive value: $96/(96 + 4980) = 2\%$			
Sensitivity: $96/(96 + 4) = 96\%$			
Specificity: $510,100/(510,100 + 4980) = 99\%$			

## ELEMENTS

1. Targeted or family screening in genetics concerns those who are at relatively high risk because of their family history. Direct gene testing is often possible, but there remains a vital role for detailed clinical examination and specialist clinical investigations, such as biochemical tests and imaging.
2. Consideration should be given to the advantages and disadvantages of presymptomatic or predictive testing from both a practical and an ethical point of view.
3. Population screening involves the offer of genetic testing to all members of a particular population, with the objectives of preventing later ill health and providing informed personal choice. A good screening test has a high sensitivity and specificity.
4. Participation should be voluntary, and each program should be widely available, equitably distributed, acceptable to the target population, and supported by full information and counseling.
5. Prenatal screening based on ultrasound examination at approximately 12 and 20 weeks' gestation is routinely available, as well as combined testing to refine the risk for aneuploidies such as Down syndrome, which may lead to the offer of amniocentesis for genetic testing of the fetus.
6. Newborn screening for phenylketonuria was introduced in the 1960s but has now expanded to incorporate a wide range of metabolic conditions, as well as hearing testing.
7. Population screening programs for carriers of  $\beta$ -thalassaemia have resulted in a major fall in the incidence of births of affected homozygotes. This has provided the paradigm for the introduction of screening for other disorders with serious long-term morbidity.
8. Well-organized genetic registers provide an effective means of identifying individuals eligible for testing and screening when new programs or modalities are introduced.

## CLINICAL SCENARIO 1

Consideration is being given to the introduction of a newborn screening program for a metabolic disease not yet covered by the current program. The criteria for early screening, in terms of the medical need, are satisfied.

The data for the new test are as follows:

Affected	Unaffected
Screening Test Result	
True positives: 115	False positives: 1312
False negatives: 22	True negatives: 460,364

Regarding this test, what is the:

- a. Sensitivity?
- b. Specificity?
- c. Positive predictive value?

## CLINICAL SCENARIO 2

With reference to **Clinical Scenario 1**, a technical modification of the screening test has been made, and it has been reevaluated.

The data for this modified new test are as follows:

Affected	Unaffected
Screening Test Result	
True positives: 83	False positives: 9529
False negatives: 2	True negatives: 348,109

Regarding this modified test, what is the:

- a. Sensitivity?
  - b. Specificity?
  - c. Positive predictive value?
- Which is the better test, this one or the earlier test (Clinical Scenario 1), and why?

## Further Reading

Axworthy D, Brock DJH, Bobrow M, Marteau TM. Psychological impact of population-based carrier testing for cystic fibrosis: 3-year follow-up. *Lancet*. 1996;347:1443–1446.

*A review of the impact of carrier testing for cystic fibrosis on over 700 individuals.*

Baily MA, Murray TH, eds. *Ethics and Newborn Genetic Screening: New Technologies, New Challenges*. Baltimore, MD: Johns Hopkins University Press; 2009.

*A multiauthor volume with a focus on the health economics of newborn screening and distributive justice.*

Harper PS. *Practical Genetic Counselling*. 7th ed. London: Hodder Arnold; 2010.

*A very good starting point in almost every aspect of genetic counseling, including carrier testing.*

Marteau T, Richards M, eds. *The Troubled Helix*. Cambridge: Cambridge University Press; 1996.

*Perspectives on the social and psychological implications of genetic testing and screening.*

Nuffield Council on Bioethics. *Genetic Screening: Ethical Issues*. London: Nuffield Council on Bioethics; 1993.

*This report remains a very helpful read even though technologies have progressed.*

## Websites

Centers for Disease Control and Prevention. Newborn Screening. (<http://www.cdc.gov/newbornscreening/>).

*A source of information on newborn screening in the United States.*

Burton H, Moorthie S. *Expanded Newborn Screening. A Review of the Evidence*. Cambridge: PHG Foundation; 2010 ([https://www.phgfoundation.org/documents/229\\_1275040921.pdf](https://www.phgfoundation.org/documents/229_1275040921.pdf)).

National Health Service websites offering information on screening programs. (<https://www.nhs.uk/conditions/nhs-screening/>; <https://phscreening.blog.gov.uk/about/>)

UK National Screening Committee (<https://www.gov.uk/government/groups/uk-national-screening-committee-uk-nsc>).

*A source of up-to-date information on screening in the United Kingdom.*

# 12

## Hemoglobin and the Hemoglobinopathies

*Blood is a very special juice.*

*Johann Wolfgang von Goethe in Faust I (1808)*

Over a quarter of a million people are born in the world each year with one of the disorders of the structure or synthesis of hemoglobin (Hb)—the hemoglobinopathies. Originally conditions of the tropics and subtropics, migration has seen these conditions have worldwide impact. In fact, the impact on morbidity and mortality is the greatest of any single group of disorders following mendelian inheritance and, as such, has served as a paradigm for our understanding of the pathology of inherited disease at the clinical, protein and DNA levels. The mobility of modern society means that new communities with a high frequency of Hemoglobinopathies have become established in countries whose indigenous populations have a low frequency. Because they are a major public health concern, many countries have introduced screening programs. In England and Wales, there are an estimated 600,000 healthy carriers of Hb variants.

To understand the various Hemoglobinopathies and their clinical consequences, it is first necessary to consider the structure, function, and synthesis of Hb.

### Structure of Hemoglobin

Hb is the protein present in red blood cells that is responsible for oxygen transport. There are approximately 15 g of Hb in every 100 mL of blood, making it amenable to analysis.

### Protein Analysis


In 1956, by fractionating the peptide products of digestion of human Hb with the proteolytic enzyme trypsin, Ingram found 30 discrete peptide fragments. Trypsin cuts polypeptide chains at the amino acids arginine and lysine. Analysis of the 580 amino acids of human Hb had previously revealed a total of 60 arginine and lysine residues, suggesting that Hb was made up of two identical peptide chains with 30 arginine and lysine residues on each chain.

At about the same time, a family was reported in which two Hb variants, HbS and Hb Hopkins II, were both present in some family members. Several members of the family who possessed both variants had children with normal Hb—offspring who were heterozygous for only one Hb variant, as well as offspring who, like their parents, were doubly heterozygous for the two Hb variants. These observations provided further evidence that at least two different genes were involved in the production of human Hb.

Soon after, the amino-terminal amino acid sequence of human Hb was determined and showed valine—leucine and valine—histidine sequences in equimolar proportions, with two moles of each of these sequences per mole of Hb. This was consistent with human Hb being made up of a tetramer consisting of two pairs of different polypeptides, referred to as the  $\alpha$ - and  $\beta$ -globin chains.

Analysis of the iron content of human Hb revealed that iron constituted 0.35% of its weight, from which it was calculated that human Hb should have a minimum molecular weight of 16,000 Daltons (Da). In contrast, determination of the molecular weight of human Hb by physical methods gave values of the order of 64,000 Da, consistent with the suggested tetrameric structure,  $\alpha_2\beta_2$ , with each of the globin chains having its own iron-containing group—heme (Fig. 12.1).

Subsequent investigators demonstrated that Hb from normal adults also contained a minor fraction, constituting 2% to 3% of the total Hb, with an electrophoretic mobility different from the majority of human Hb. The main component was called HbA, whereas the minority component was called HbA<sub>2</sub>. Subsequent



• **Fig. 12.1** Diagrammatic representation of one of the globin chains and associated porphyrin molecule of human hemoglobin.



### • BOX 16.2 Isolated (Non-syndromal) Malformations That Show Multifactorial Inheritance

#### Cardiac

Atrial septal defect  
Tetralogy of Fallot  
Patent ductus arteriosus  
Ventricular septal defect

#### Central Nervous System

Anencephaly  
Encephalocele  
Spina bifida

#### Genitourinary

Hypospadias  
Renal agenesis  
Renal dysgenesis

#### Other

Cleft lip/palate  
Congenital dislocation of hips  
Talipes

declines but remains higher than among the indigenous population. These observations suggest the presence of susceptibility genes in Celtic populations.



• Fig. 16.17 A baby with a large occipital encephalocele.

No single NTD susceptibility gene has been identified in humans, although there is some evidence that the common 677C > T polymorphism in the *methylenetetrahydrofolate reductase* (*MTHFR*) gene can be a susceptibility factor in some populations. Reduction in *MTHFR* activity results in decreased plasma folate levels, which are known to be causally associated with NTDs (see the following section). Research efforts have also focused on developmental genes, such as genes belonging to the *PAX* family (p. 113), which are expressed in the embryonic neural tube and vertebral column. In mouse models, approximately 80 genes have been linked to exencephaly, approximately 20 genes to lumbosacral myelomeningocele, and approximately five genes to craniorachischisis. One example is an interaction between mutations of *PAX1* and the *platelet-derived growth factor α* gene (*PDGFRA*) that results in severe NTDs in 100% of double-mutant embryos. This rare example of digenic inheritance (p. 76) serves as a useful illustration of the difficulties posed by a search for susceptibility genes in a multifactorial disorder. However, to date there have been no equivalent breakthroughs in understanding the processes in human NTDs.


Environmental factors include poor socioeconomic status, multiparity, and valproic acid (VPA) exposure (p. 240, Fig. 16.20). Firm evidence has also emerged that periconceptional multivitamin supplementation reduces the risk of recurrence by a factor of 70% to 75% when a woman has had one affected child. Studies have shown that folic acid is likely to be the effective constituent in multivitamin preparations, and the World Health Organization recommends periconceptional folate supplementation of 400 µg/day, which is adopted in some form by most nations. In some countries, including the United States, bread is fortified with folic acid. Many nations officially recommend that all women who have previously had a child with an NTD should take 4 to 5 mg of folic acid daily, both before conceiving and throughout the first trimester.

### Environmental Agents (Teratogens)

An agent that can cause a birth defect by interfering with normal embryonic or fetal development is known as a teratogen. Many teratogens have been identified, and exhaustive tests are now undertaken before any new drug is approved for use by pregnant women. The potential effects of any particular teratogen usually depend on the dosage and timing of administration during pregnancy, along with the susceptibility of both the mother and fetus.

An agent that conveys a high risk of teratogenesis, such as the rubella virus or the iodide, can usually be identified relatively quickly. Unfortunately, it is much more difficult to detect a low-grade teratogen that causes an abnormality in only a small proportion of cases. This is because of the relatively high background incidence of congenital abnormalities, and also because many pregnant women take medication at some time in pregnancy, often for a poorly-defined “flu-like” illness. Despite extensive study, controversy still surrounds the use of a number of drugs in pregnancy. The anti-nausea drug *Debendox* was the subject of successful litigation in the United States despite a lack of firm evidence to support a definite teratogenic effect. A group of drugs under scrutiny more recently is the selective serotonin reuptake inhibitors. These are commonly prescribed antidepressants, and in Europe some 3% of pregnant women take antidepressants, rising to approximately 8% in the United States. Despite concerns about a teratogenic potential, particularly congenital heart disease, several large studies have failed to demonstrate a significant difference in the frequency of birth defects.





• **Fig. 17.17** Deletion 22q11.2 (DiGeorge/Sedláčková/velocardiofacial) syndrome. (A) A young infant. (B) A young child. (C) An older child. (D) The same individual shown in (C) as an adult aged 49 years.

### Deletion 1p36 Syndrome

This microdeletion syndrome emerged through improved cytogenetic techniques and the use of FISH in the 1990s. In keeping with the modern approach to nomenclature, deletion 1p36 syndrome has no eponym. The features are hypotonia, microcephaly, growth delay, severe learning difficulties, epilepsy (including infantile spasms), characteristically straight eyebrows with slightly deep-set eyes, and midface hypoplasia (Fig. 17.21). Some cases develop dilated cardiomyopathy.

### Deletion 9q34 (Kleefstra) Syndrome

Another of the relatively new microdeletion syndromes, this was first reported as a condition featuring significant ID, hypotonia, obesity, brachycephaly, arched eyebrows, synophrys, anteverted nostrils, prognathism, sleep disturbances, and behavioral problems. Many patients have severe speech delay, and not all manifest obesity. The case pictured in Fig. 17.22 bears a passing resemblance to Angelman syndrome. As with some of the other microdeletion syndromes (e.g., Smith-Magenis), some patients with the phenotypic features but no microdeletion have been shown to have mutations in the

euchromatin histone methyl transferase 1 (*EHMT1*) gene, which lies within the region. The syndrome might therefore be mainly caused by haploinsufficiency for this gene.

### Deletion 17q21.31 (Koolen-de Vries) Syndrome

This was one of the first new deletion syndromes delineated through CMA, has a prevalence of approximately 1:16,000 and is probably significantly underdiagnosed. The main features are severe ID, hypotonia and characteristic facial dysmorphisms including a long face with a high forehead and tubular or pear-shaped nose, a bulbous nasal tip, large ears, and everted lower lip (Fig. 17.23). Individuals tend to be friendly. Other clinically important features include epilepsy, heart defects, kidney anomalies, and long, slender fingers. The *KANSL1* gene is key, and there are patients with pathogenic variants who do not have CMA-detectable deletions.

### Deletion 22q13 (Phelan-McDermid) Syndrome

Understanding of this condition, which is distinct from the better-known deletion 22q11.2 (DiGeorge) syndrome, predated the CMA era as cases with cytogenetically visible deletions were